Sensitive skin is traditionally viewed as a neuro-sensory disorder, whereas hyperpigmentation is considered an outcome of melanocyte over-activity. Clinical observation, however, shows that SS patients frequently develop stubborn PIH after minimal irritation, suggesting a deeper molecular crosstalk that has remained largely unexplored.
Using the GeneCards database, the team constructed disease-gene networks for SS and PIH, then intersected them to reveal 164 shared targets. The combination of PPI network, KEGG and GO analysis revealed the key role of tyrosinase and immune-mediated inflammation in pigmentation on sensitive skin. Among the 15 active compounds, oxyresveratrol was identified as having a high correlation with the core set targets and predicted strong inhibition of Tyrosine-protein Kinase Kit. The application of oxyresveratrol exhibited a dose-dependent suppression of melanin production in B16F10 cells.
This study suggested the crucial roles of immune-mediated inflammation in sensitive skin and hyperpigmentation, as well as highlighted the potential of oxyresveratrol in addressing hyperpigmentation on sensitive skin. These comprehensive findings provide a deeper understanding of the connection mechanism between sensitive skin and hyperpigmentation, offering new insights for the development of targeted treatments and interventions.
Journal of Dermatologic Science and Cosmetic Technology
Experimental study
Not applicable
Network pharmacology and molecular docking reveal the potential inner mechanism between sensitive skin and hyperpigmentation
11-Jan-2025
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Jianhua Zhang reports financial support was provided by N.0.D topia (GuangZhou) Biotechnology Co.Ltd., Guangzhou, China. Jianhua Zhang reports a relationship with N.0.D topia (Guangzhou)Biotechnology Co., Ltd., Guangzhou, China that includes: employment and equity or stocks. Shichao Liureports a relationship with N.0.D topia (GuangZhou) Biotechnology Co, Ltd., Guangzhou, China thatincludes: employment and equity or stocks. Wenjiao Guo reports a relationship with N.0.D topiaGuangZhou) Biotechnology Co., Ltd., Guangzhou, China that includes: employment. Li Lin reports arelationship with Foshan Conney Allan Biotechnology Co., Ltd., Foshan, china that includes: employmentand equity or stocks. Corresponding author Jianhua Zhang and co-author Zhiyun Du are Editorial BoardMember/Editor-in-Chief for Journal of Dermatologic Science and Cosmetic Technology and were notinvolved in the editorial review or the decision to publish this article. lfthere are other authors, theydeclare that they have no known competing financial interests or personal relationships that could haveappeared to influence the work reported in this paper.